VSuzanne Suzanne Klimberg

Dr. VSuzanne Suzanne Klimberg


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2017 in Surgical Oncology Clinics of North America
Verified
Journal Article
Closed access
KBKayla Barnard
Kayla Barnard
VKVSuzanne Suzanne Klimberg
VSuzanne Suzanne Klimberg

18 January 2026 in Annals of Surgical Oncology
Verified
Journal Article
Open access
KGKristalyn Gallagher
Kristalyn Gallagher
SFSheldon Feldman
Sheldon Feldman
JBJulie Barone
Julie Barone
JMJoshua Mammen
Joshua Mammen
RBRobert Barone
Robert Barone
VKVSuzanne Suzanne Klimberg
VSuzanne Suzanne Klimberg
Background: Excision followed by radiofrequency ablation (eRFA) is an intraoperative method that utilizes intracavitary hyperthermia to create an additional tumor-free zone around the lumpectomy cavity in patients with breast cancer, similar to partial breast irradiation. We hypothesized that intraoperative eRFA extends the “final” tumor-free margin, decreases local recurrence, and maintains cosmesis without the need for radiation (XRT). Patients and Methods: Patients with unifocal ER+PR+HER2− or DCIS tumors less than or equal to 3 cm with clinically negative nodes were included. After standard lumpectomy, the RFA probe was deployed 1 cm circumferentially into the walls of the lumpectomy cavity. RFA was performed at 100°C for 15 min, followed by validated intraoperative Doppler sonography. Pain and cosmesis were assessed with the Radiation Therapy Oncology Group (RTOG) scales. Results: A total of 242 subjects were accrued to the study, with a median follow-up of 44 months (range 12–96 months); 60% were invasive ductal cancer (IDC), and 33% were ductal carcinoma in situ (DCIS). The average size was 1.1 ± 0.6 cm (0.2–3 cm). Reexcision for positive margins was < 5%. In-breast recurrence rate was 2.9%. Breast pain at 6 months was 19% with RFA combined with XRT versus 1.7% with RFA alone ( p < 0.05). Cosmesis was good or excellent in 89% of subjects. Conclusions: A majority of the subjects avoided whole breast XRT and mastectomy. Results indicate that eRFA, in lieu of XRT, is safe and effective, resulting in ~fivefold lower pain. By completing therapy in the operating room, eRFA can potentially enhance patient access and compliance, alleviate financial stress, and deliver superior cosmetic and quality-of-life outcomes.

20 November 2025 in The American Journal of Surgery
Verified
Journal Article
Closed access
JDJennifer Den
Jennifer Den
CBCaroline Baughn
Caroline Baughn
VKVSuzanne Suzanne Klimberg
VSuzanne Suzanne Klimberg


13 February 2024 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
KBKirby I. Bland
Kirby I. Bland
VKVSuzanne Suzanne Klimberg
VSuzanne Suzanne Klimberg

29 October 2025 in Annals of Surgical Oncology
Verified
Journal Article
Open access
PDF file
VKVSuzanne Suzanne Klimberg
VSuzanne Suzanne Klimberg
Common, persistent, and debilitating, breast cancerrelated lymphedema (BCRL) is frequently underdiagnosed and undertreated. It is a significant burden on both the